TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SI-Bone ( (SIBN) ) has shared an update.
On November 6, 2025, Daniel Wolf resigned from SI-BONE’s Board of Directors, and Thomas A. West was appointed to the Board’s Audit Committee. Despite his resignation, Mr. Wolf will continue to support the company through a consulting agreement focusing on marketing, strategy, and business development. In the third quarter of 2025, SI-BONE reported a 20.6% increase in worldwide revenue to $48.7 million, with a positive adjusted EBITDA of $2.3 million. The company also raised its 2025 revenue guidance, reflecting strong demand for its differentiated platform and a robust increase in the number of active physicians. This financial performance underscores SI-BONE’s strong industry positioning and its ability to self-fund innovation and growth.
The most recent analyst rating on (SIBN) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on SI-Bone stock, see the SIBN Stock Forecast page.
Spark’s Take on SIBN Stock
According to Spark, TipRanks’ AI Analyst, SIBN is a Neutral.
SI-Bone’s overall stock score is driven by strong earnings call performance, highlighting significant revenue growth and operational milestones. However, financial performance challenges, particularly in profitability and cash flow management, weigh heavily on the score. Technical indicators suggest a neutral trend, while valuation metrics reflect ongoing profitability issues. The company’s strategic focus on innovation and market expansion is a positive factor, but financial health improvements are necessary for a higher score.
To see Spark’s full report on SIBN stock, click here.
More about SI-Bone
SI-BONE, Inc. is a global leader in developing unique technologies for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, the company has supported over 4,900 physicians in performing more than 135,000 procedures. SI-BONE leverages its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation, and pelvic trauma.
Average Trading Volume: 395,335
Technical Sentiment Signal: Hold
Current Market Cap: $680.3M
See more data about SIBN stock on TipRanks’ Stock Analysis page.